Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 31:8:570.
doi: 10.7916/D8FF58Z9. eCollection 2018.

Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review

Anelyssa D'Abreu  1 , Joseph H Friedman  2
Affiliations
Review

Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review

Anelyssa D'Abreu et al. Tremor Other Hyperkinet Mov (N Y). .

Abstract

Background: Although tardive dyskinesia (TD) is most commonly defined as a movement disorder caused by chronic exposure to dopamine-receptor-blocking drugs (DRBDs), it has also been thought to result from exposure to some non-DRBDs.

Methods: We critiqued many reviews making the association between non-DRBDs and a TD-like syndrome and almost all case reports. We checked whether cases met criteria for the diagnosis of TD-like syndrome and whether DRBDs had been excluded.

Results: We found that both tricyclic antidepressants and selective serotonin reuptake inhibitor antidepressants may unmask or exacerbate TD after prior exposure to or with concurrent use of DRBDs. We found support for its existence outside of this context to be extremely weak.

Discussion: There is little evidence that drugs other than DRBDs by themselves cause a TD syndrome; most reported cases appear to occur as a result of a "priming" effect induced by a DRBD, which is later unmasked.

Keywords: Anticholinergics; Antidepressants; Antiepileptics; Antihistamine; Non-dopamine receptor antagonists; Tardive Dyskinesia.

PubMed Disclaimer

Conflict of interest statement

Funding: None. Conflict of Interests: Paid consultant to Acadia Pharmaceuticals; royalties from Springer and Cambridge University Presses; research funding from NIH and MJ Fox Foundation. Ethics Statement: This study was reviewed by the authors' institutional ethics committee and was considered exempted from further review.

Comment in

References

    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders (5th ed.) Arlington, VA: American Psychiatric Publishing; 2013.
    1. Wain OJ J. Tardive dyskinesia. In: Roos RP, editor. Neurology. San Diego: MedLink Corporation; 2017. editor. Available at wwwmedlinkcom, last updated February 27.
    1. Mander A, McCausland M, Workman B, Flamer H, Christophidis N. Fluoxetine induced dyskinesia. Aust NZ J Psychiatry. 1994;28:328–330. doi: 10.1080/00048679409075647. - DOI - PubMed
    1. Clayton AH. Antidepressant-induced tardive dyskinesia: review and case report. Psychopharmacol Bull. 1995;31:259–264. - PubMed
    1. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57:449–454. doi: 10.4088/JCP.v57n1002. - DOI - PubMed

LinkOut - more resources